GlaxoSmithKline Pharmaceuticals Ltd. - Research Center
500660 GLAXO Group (A) BSE data
Results
|
Half yearly
|
Statement
|
|
More
|
|
Half yearly results in brief
(Rs crore)
|
Sep ' 23 |
Sep ' 22 |
Mar ' 22 |
Sep ' 21 |
Sep ' 20 |
Sales |
1,691.40 |
1,635.07 |
1,599.90 |
1,764.99 |
1,528.04 |
Operating profit |
427.83 |
404.85 |
370.08 |
425.08 |
319.37 |
Interest |
0.71 |
1.07 |
0.85 |
1.14 |
1.96 |
Gross profit |
492.39 |
453.73 |
398.67 |
470.72 |
384.12 |
EPS (Rs) |
20.43 |
18.43 |
80.72 |
19.07 |
11.07 |
Half yearly
results in details
|
Sep ' 23 |
Sep ' 22 |
Mar ' 22 |
Sep ' 21 |
Sep ' 20 |
Other income |
65.27 |
49.95 |
29.44 |
46.78 |
66.71 |
Stock adjustment |
-34.67 |
-116.86 |
7.88 |
4.25 |
-22.82 |
Raw material |
225.18 |
255.53 |
240.13 |
312.25 |
252.33 |
Power and fuel |
- |
- |
- |
- |
- |
Employee expenses |
310.21 |
293.16 |
282.43 |
327.80 |
305.93 |
Excise |
- |
- |
- |
- |
- |
Admin and selling expenses |
- |
- |
- |
- |
- |
Research and development expenses |
- |
- |
- |
- |
- |
Expenses capitalised |
- |
- |
- |
- |
- |
Other expenses |
762.85 |
798.39 |
699.38 |
695.61 |
673.23 |
Provisions made |
- |
- |
- |
- |
- |
Depreciation |
34.47 |
32.18 |
33.22 |
35.31 |
43.73 |
Taxation |
129.10 |
112.36 |
295.34 |
112.36 |
88.80 |
Net profit / loss |
346.12 |
312.24 |
1,367.47 |
323.05 |
187.46 |
Extra ordinary item |
17.30 |
3.05 |
1,297.36 |
- |
-64.13 |
Prior year adjustments |
- |
- |
- |
- |
- |
Equity capital |
169.41 |
169.41 |
169.41 |
169.41 |
169.41 |
Equity dividend rate |
- |
- |
- |
- |
- |
Agg.of non-prom. shares (Lacs) |
- |
- |
- |
- |
- |
Agg.of non promotoholding (%) |
- |
- |
- |
- |
- |
OPM (%) |
25.29 |
24.76 |
23.13 |
24.08 |
20.90 |
GPM (%) |
28.03 |
26.93 |
24.47 |
25.98 |
24.09 |
NPM (%) |
19.70 |
18.53 |
83.93 |
17.83 |
11.75 |